Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 9;27(17):4848–4858. doi: 10.1158/1078-0432.CCR-20-4219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.

PMC Copyright notice

Figure 4. Associations between baseline serum biomarkers and OS. A, Associations between treatment arms and OS by baseline serum biomarker-level group. B, Kaplan–Meier plot showing associations by high or low baseline serum biomarker levels of FGF21 [cutoff level of 0.75 (= 688.0 ng/L)] and OS. ANG2, angiopoietin-2; C, cycle; CI, confidence interval; D, day; FGF, fibroblast growth factor; HR, hazard ratio; LEN, lenvatinib; OS, overall survival; SOR, sorafenib; VEGF, vascular endothelial growth factor. — Associations between baseline serum biomarkers and OS. A, Associations between treatment arms and OS by baseline serum biomarker-level group. B, Kaplan–Meier plot showing associations by high or low baseline serum biomarker levels of FGF21 [cutoff level of 0.75 (= 688.0 ng/L)] and OS. ANG2, angiopoietin-2; C, cycle; CI, confidence interval; D, day; FGF, fibroblast growth factor; HR, hazard ratio; LEN, lenvatinib; OS, overall survival; SOR, sorafenib; VEGF, vascular endothelial growth factor.